HDP-101

Heidelberg Pharma AG · Phase 1 active Small molecule

At a glance

Generic name	HDP-101
Sponsor	Heidelberg Pharma AG
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HDP-101 CI brief — competitive landscape report
HDP-101 updates RSS · CI watch RSS
Heidelberg Pharma AG portfolio CI